Table 1.
PwMS baseline data
| Exposed (N = 24) | Controls (N = 24) | Total (N = 48) | P | |
|---|---|---|---|---|
| Disease type | ||||
| PP | 0 (0%) | 1 (4.2%) | 1 (2.1%) | 0.235a |
| RR | 20 (83.3%) | 22 (91.7%) | 42 (87.5%) | |
| SP | 4 (16.7%) | 1 (4.2%) | 5 (10.4%) | |
| Years from onset | ||||
| Mean ± SD | 10.5 ± 8.2 | 16.1 ± 11.1 | 13.3 ± 10.1 | 0.054b |
| Median [range] | 9 [0, 27] | 14 [3, 43] | 13 [0, 43] | 0.070c |
| Years from diagnosis | ||||
| Mean ± SD | 8.2 ± 7.3 | 10.5 ± 8.5 | 9.3 ± 7.9 | 0.312b |
| Median [range] | 7 [0, 27] | 9 [0, 33] | 8 [0, 33] | 0.269c |
| EDSS grade prestudy | ||||
| Mean ± SD | 3.15 ± 1.97 | 3.44 ± 2.01 | 3.29 ± 1.97 | 0.666d |
| Median [range] | 2.75 [1.0, 6.5] | 3.50 [0.0, 7.5] | 3.50 [0.0, 7.5] | |
| Therapy pre-study, N (%) | ||||
| None | 6 (25.0%) | 7 (29.2%) | 13 (27.1%) | |
| First line (immunomodulatory) | 15 (62.5%) | 12 (50.0%) | 27 (56.2%) | |
| Second line | 3 (12.5%) | 5 (20.8%) | 8 (16.7%) | |
| Antispastic ± fatigue | 3 (12.5%) | 3 (12.5%) | 6 (12.5%) | |
| Analgesic | 6 (25.0%) | 3 (12.5%) | 9 (18.7%) | |
| Antidepressant ± benzodiazepine | 8 (16.7%) | 6 (25.0%) | 14 (29.2%) | |
aChi square
bWelch–Satterthwaite t test
cMann–Whitney U test
d P from ANOVA, adjusted for sex, age, and years from onset